Viyash Scientific Limited has successfully concluded its postal ballot process, with shareholders approving four critical special resolutions related to key leadership appointments and employee stock options. The voting process, which ended on March 12, 2026, demonstrated strong shareholder confidence in the company's strategic direction.

Leadership Appointments Receive Strong Support

The postal ballot results revealed overwhelming shareholder approval across all proposed resolutions. The most significant appointment was Dr. Haribabu Bodepudi (DIN: 01119687) as Managing Director and Group CEO for a two-year term, which received 97.32% approval from voting shareholders.

Comprehensive Voting Participation

The postal ballot process witnessed significant participation from the company's shareholder base. With 1,33,361 total shareholders on the record date of February 06, 2026, the voting was conducted entirely through electronic means via National Securities Depository Limited (NSDL) platform.

Shareholder Category Participation

The voting pattern showed strong support across different shareholder categories:

• Promoter and Promoter Group: Achieved 100% participation with unanimous approval across all resolutions
• Public Institutions: Demonstrated 74.52% voting participation with varying approval rates
• Public Non-Institutions: Showed participation rates ranging from 19.87% to 36.02% with high approval percentages

Stock Options Authorization

Shareholders approved the grant of stock options exceeding 1% of the company's issued capital to an identified employee within one year. This resolution received 97.32% approval, indicating strong shareholder confidence in the company's talent retention and incentive strategies.

Regulatory Compliance and Process

The postal ballot was conducted in strict compliance with Section 110 of the Companies Act, 2013, and Rule 22 of the Companies (Management and Administration) Rules, 2014. Nishant Darak & Associates served as the scrutinizer for the voting process, ensuring transparency and fairness.

Timeline and Process Details

The company utilized electronic voting exclusively, following MCA Circular No. 14/2020 and subsequent amendments, which provided shareholders with a secure and efficient voting mechanism. All resolutions are deemed passed as of March 12, 2026, the last date of remote e-voting, marking a significant milestone in the company's governance and leadership structure.

Sequent Scientific Limited, now operating as Viyash Scientific Limited, has successfully completed the distribution of proceeds from fractional shares to eligible shareholders following its composite amalgamation scheme. The company submitted comprehensive reports from its Audit Committee and Independent Directors to BSE and NSE on March 10, 2026, certifying compliance with regulatory requirements.

Amalgamation Scheme Implementation

The composite scheme of amalgamation involving Viyash Scientific Limited and multiple entities including Symed Labs Limited, Vandana Life Sciences Private Limited, and several other companies received approval from the National Company Law Tribunal (NCLT), Hyderabad bench on November 18, 2025. The scheme became effective from December 16, 2025, with the record date set as December 8, 2025.

Under the approved share exchange ratio, eligible equity shareholders of the amalgamating company received 56 fully paid-up equity shares of INR 2 each in Viyash Scientific for every 100 fully paid-up equity shares of INR 10 each held in the amalgamating company. The company allotted a total of 18,19,21,827 fully paid-up equity shares to eligible shareholders, including 13 shares allocated for fractional entitlements.

Fractional Share Distribution Details

PNB Investment Services Limited was appointed as trustee to hold the fractional shares in trust on behalf of eligible fractional shareholders. The fractional shares were sold in the open market on February 27, 2026, within the mandatory 90-day period from the date of allotment.

Regulatory Compliance and Certification

The distribution process was conducted in strict compliance with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, and SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Both the Audit Committee and Independent Directors reviewed comprehensive documentation including board resolutions, NCLT orders, valuation reports, and certificates from practicing chartered accountants.

The Audit Committee, chaired by Mr. Milind Sarwate and comprising Dr. Kamal Sharma, Ms. Revati Kasture, and Mr. Anuj Poddar, certified that the fractional shares were sold within the stipulated timeframe and proceeds were distributed proportionally to eligible shareholders. The Independent Directors, including Dr. Kamal Sharma, Mr. Milind Sarwate, and Ms. Revati Kasture, provided similar certification confirming compliance with the scheme provisions.

Distribution Timeline and Process

The net sale proceeds were successfully credited to the respective bank accounts of all 25 eligible shareholders on March 6, 2026, and March 9, 2026. The distribution was completed in proportion to each shareholder's fractional entitlement, ensuring fair and equitable treatment of all stakeholders involved in the amalgamation process.

The completion of this distribution marks a significant milestone in the amalgamation process, demonstrating the company's commitment to regulatory compliance and shareholder protection. All newly allotted equity shares rank pari-passu with existing fully paid-up equity shares of the company, providing equal rights and benefits to all shareholders.